Sign in
Knowstox

Fundamentals snapshot

PDS Biotechnology Corporation

PDSB · NCM · Healthcare · Biotechnology

Current price

$1.15

52-week range

$0.20 - $1.79

Market cap

$83.35M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-5.91x Concerning

Net cash $1.23M. Interest coverage shows how many times profit covers the interest bill.

What this company does

PDS Biotechnology Corporation

PDS Biotechnology Corporation is developing new medicines that aim to help the body's own immune system fight cancer. Their main source of potential money comes from these experimental drugs, like their lead candidate PDS0101, which is being tested in human trials for various cancers. This matters because if their treatments are successful and approved, they could offer new options for patients and generate significant revenue for the company.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $-8.00M FY2024 Q4 $-8.23M FY2025 Q2 $-9.10M FY2025 Q3 $-5.92M FY2025 Q4 $-3.70M
Revenue —
Net income $-9.75M
Diluted EPS -0.18
Operating cash flow $-2.79M
Free cash flow —
Revenue —
Net income $-7.35M
Diluted EPS -0.13
Operating cash flow $-4.37M
Free cash flow —
Revenue —
Net income $-7.56M
Diluted EPS -0.13
Operating cash flow $-3.70M
Free cash flow $-3.70M
Revenue —
Net income $-9.01M
Diluted EPS -0.19
Operating cash flow $-5.92M
Free cash flow $-5.92M
Revenue —
Net income $-9.43M
Diluted EPS -0.21
Operating cash flow $-9.10M
Free cash flow $-9.10M
Revenue —
Net income $-8.49M
Diluted EPS -0.21
Operating cash flow $-9.03M
Free cash flow —
Revenue —
Net income $-7.95M
Diluted EPS -0.21
Operating cash flow $-8.23M
Free cash flow $-8.23M
Revenue —
Net income $-10.73M
Diluted EPS -0.29
Operating cash flow $-8.00M
Free cash flow $-8.00M

Is it cheap or expensive?

Fair value — vs current price $1.15

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $1.2M - more cash than debt. Interest coverage -5.9x.

Net debt $-1.23M
Interest coverage -5.91x

PDS Biotechnology Corporation is healthier than 0 of 1 peers on balance-sheet leverage.

Healthy
Worse cushion Baseline Better cushion
PDSB BASELINE PDS Biotechnology Corporation

Total debt $4.36M Interest coverage -5.91x This is the baseline the peer rows are being compared against.

-5.91x

What you should know

The case for and against PDSB

0 Rewards 1 Risk

Rewards

Risks

  • Return on equity was -544.0% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-3.33x
P/B
-17.97x
P/S
—
EV/EBITDA
-2.46x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-544.0%
ROA
-70.6%

Health

Liquidity and balance-sheet strength

Debt / equity
—
Current ratio
0.57x
Quick ratio
0.45x
Total debt
$4.36M
Total cash
$5.60M

Growth

How the business has been compounding

Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.64
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-16.78M
Free CF TTM
$-27.75M
FCF margin
—

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
—
Last ex-div date
—